Clinical trials: Pembrolizumab
Metastatic Breast Cancer
Phase 1b Study of Pegylated Liposomal Doxorubicin and Pembrolizumab in Endocrine-resistant Breast Cancer
Very few patients with endocrine-resistant, hormone-receptor positive metastatic breast cancer respond to single agent immunotherapy. Responses to chemotherapy are usually of short duration.
- Trial name
- KEYDOX (NCT03591276)
- Testing
- Chemotherapy Drugs, Cancer
- Where
- Israel
- Volunteers
- 15 people
- Sponsor
- Shaare Zedek Medical Center
Mycosis Fungoides, Mycosis Fungoides/Sezary Syndrome
Pembrolizumab in Combination With Gemcitabine in People With Advanced Mycosis Fungoides or Sézary Syndrome
The purpose of this study is to find out whether the combination of pembrolizumab and gemcitabine is an effective treatment for mycosis fungoides and Sézary syndrome.
- Conditions
- Mycosis Fungoides, Mycosis Fungoides/Sezary Syndrome, Sezary Syndrome, Sézary
- Trial name
- NCT04960618
- Testing
- Gemcitabine, Pembrolizumab
- Where
- 8 sites in United States
- Volunteers
- 14 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8
Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the Treatment of Stage III-IV Triple Negative Breast Cancer
This phase II trial tests whether panitumumab and pembrolizumab in combination with standard of care chemotherapy before surgery (neoadjuvant) works to shrink tumors in patients with stage III-IV triple negative breast cancer.
- Conditions
- Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8
- Trial name
- NCT05177796
- Testing
- Carboplatin, Cyclophosphamide, Doxorubicin
- Where
- United States
- Sponsor
- M.D. Anderson Cancer Center
Adenocarcinoma of Esophagogastric Junction, Neoadjuvant Chemotherapy
Pembrolizumab Plus Neoadjuvant Chemotherapy for Locally Advanced EGJ Adenocarcinoma
The purpose of this study is to observe and evaluate the efficacy and safety of pembrolizumab plus cisplatin and 5-fluorouracil (5-FU) followed Surgery for locally advanced adenocarcinoma of esophagogastric junction
- Conditions
- Adenocarcinoma of Esophagogastric Junction, Neoadjuvant Chemotherapy, Pembrolizumab
- Trial name
- KEYSTONE-003 (NCT04813523)
- Testing
- Pembrolizumab Injection [Keytruda]
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Non-small Cell Lung Cancer (NSCLC)
A Trial of CV301 in Combination With Anti-PD-1 Therapy in Subjects With Non-Small Cell Lung Cancer
The objective of the proposed clinical trial is to investigate the safety and tolerability of CV301 in combination with Anti-PD1-Therapy in subjects with non-small cell lung cancer (NSCLC).
- Trial name
- NCT02840994
- Testing
- CV301, Pembrolizumab, Nivolumab
- Where
- 7 sites in United States
- Volunteers
- 24 people
- Sponsor
- Bavarian Nordic
Locally Advanced Head and Neck Cancer
Concomitant Immune Check Point Inhibitor With Radiochemotherapy in Head And Neck Cancer
Background: Locally advanced head and neck cancer (HNC) is a challenge as, in spite of initial good control with chemoradiation, the majority of patients fails systemically.
- Trial name
- NCT03532737
- Testing
- Pembrolizumab
- Where
- Kuwait
- Volunteers
- 50 people
- Sponsor
- Kuwait Cancer Control Center
Colorectal Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma
Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer
This phase Ib trial studies the side effects and best dose of Hsp90 inhibitor XL888 when given together with pembrolizumab in treating patients with advanced gastrointestinal cancer that has spread to other places in the body.
- Conditions
- Colorectal Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Recurrent Colorectal Carcinoma, Recurrent Pancreatic Carcinoma
- Trial name
- NCT03095781
- Testing
- XL888, Pembrolizumab
- Where
- 3 sites in United States
- Volunteers
- 47 people
- Sponsor
- Emory University
Advanced Upper Tract Urothelial Carcinoma
Real-World Outcomes of First-Line Treatment of Metastatic or Locally Advanced Upper Tract Urothelial Carcinoma With Enfortumab Vedotin Plus Pembrolizumab : A French Multicenter Retrospective Observational Study
The combination of Enfortumab Vedotin and Pembrolizumab has substantially improved outcomes for patients with advanced urothelial carcinoma and has emerged as a new standard of care in the first-line setting.
- Trial name
- UTUC PROVE (NCT07633353)
- Testing
- enfortumab vedotin plus pembrolizumab in first line setting for advanced upper tract urothelial carcinoma
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Prostate Cancer
Phase 2 Study of Neoadjuvant PEMbrolizumab Before Radical PROstatectomy in High-risk Prostate Cancer Patients
This is a phase 2, open-label, non-randomized, single-arm study in patients with high-risk PCa diagnosed with prostate biopsy and undergoing RP and ePLND.
- Trial name
- PEM-PRO (NCT04565496)
- Testing
- Pembrolizumab
- Where
- 2 sites in Italy
- Sponsor
- IRCCS San Raffaele
Bladder Cancer
Study of Pembrolizumab (MK-3475) and Pembrolizumab With Other Investigational Agents in Participants With High Risk Non-muscle Invasive Bladder Cancer (MK-3475-057/KEYNOTE-057)
In this study, participants with high risk non-muscle-invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette Guerin (BCG) therapy and who are considered ineligible for or have refused to undergo radical cystectomy…
- Trial name
- NCT02625961
- Testing
- Pembrolizumab, Pembrolizumab/vibostolimab coformulation, Favezelimab/pembrolizumab coformulation
- Volunteers
- 296 people
- Sponsor
- Merck Sharp & Dohme LLC
Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
Optimizing Antitumor Immunity Using Plasmid Electroporation, Pembrolizumab, and Epacadostat
This phase II trial studies how well tavokinogene telseplasmid with electroporation (tavo-EP), pembrolizumab, and epacadostat work in treating patients with squamous cell carcinoma of the head and neck that cannot be removed by…
- Conditions
- Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Unresectable Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT03823131
- Testing
- ImmunoPulse, Epacadostat, Pembrolizumab
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Chase Heaton, MD
Carcinoma, Non-Small-Cell Lung
MK-3475 and Gemcitabine in Non-Small Cell Lung Cancer (NSCLC)
This is a study for patients with previously-treated advanced non-small cell lung cancer (NSCLC). The study will evaluate the safety of adding an investigational drug, MK-3475 to standard treatment with gemcitabine.
- Trial name
- NCT02422381
- Testing
- MK-3475, Gemcitabine
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- Providence Health & Services
Advanced Solid Tumors
A Phase 1 Study of ASKG315 in Patients With Advanced Solid Tumors
The study is a Phase 1, open-label, multicenter, dose escalation study to evaluate the safety, tolerability, PK and PD of ASKG315 as a single agent (Part 1) and in combination with pembrolizumab (Part 2) in patients with advanced…
- Trial name
- NCT05509985
- Testing
- ASKG315
- Where
- 2 sites in Australia
- Volunteers
- 100 people
- Sponsor
- AskGene Pharma, Inc.
Recurrent Endometrial Cancer, Solid Tumors
Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System
This is a study of pembrolizumab in combination with sitravatinib in adult women with recurrent endometrial cancer or other solid tumors with deficient mismatch repair system.
- Trial name
- NCT05419817
- Testing
- pembrolizumab, Sitravatinib
- Sponsor
- Haider Mahdi
Carcinoma, Non-Small-Cell Lung
A Clinical Study of Bemcentinib With Standard of Care Chemoimmunotherapy in Untreated Advanced/Metastatic Non-small Cell Lung Cancer Patients With a Mutation in the STK11 Gene
The primary purpose of this study is to determine the safety and tolerability of the combination of bemcentinib with chemo-immunotherapy (CIT) to identify the recommended phase 2 dose (RP2D) when administered as first line (1L)…
- Trial name
- NCT05469178
- Testing
- Bemcentinib, Pembrolizumab, Pemetrexed
- Where
- 34 sites in United States, France and 5 more
- Volunteers
- 26 people
- Sponsor
- BerGenBio ASA
Neoadjuvent, PD-1 Inhibitor
Neoadjuvant Therapy for Stage II-IVA Resectable Esophageal Squamous Cell
The aim of this study was to investigate the efficacy and safety of pembrolizumab combined with albumin paclitaxel and cisplatin versus albumin paclitaxel and cisplatin or 5-fluorouracil and cisplatin in neoadjuvant therapy for…
- Conditions
- Neoadjuvent, PD-1 Inhibitor, Chemotherapy, Esophageal Squamous Cell Carcinoma
- Trial name
- NCT06006650
- Testing
- Pembrolizumab, Albumin Paclitaxel, 5-fluorouracil, Cisplatin
- Where
- 3 sites in China
- Volunteers
- 114 people
- Sponsor
- Tang-Du Hospital
Solid Tumor
Nivolumab and Pembrolizumab Dose Optimisation in Solid Tumours With CURATE.AI Platform and Sequential ctDNA Measurements
CURATE.AI - a small data, AI-derived technology platform - allows personalised guidance of an individual's dose modulations based only on that individual's data.
- Trial name
- NCT05175235
- Testing
- CURATE.AI, Nivolumab, Pembrolizumab
- Where
- Singapore
- Volunteers
- 10 people
- Sponsor
- National University Hospital, Singapore
Non Small Cell Lung Cancer
Circulating Tumor DNA Alterations in Non-small Cell Lung Cancer Patients Treated With Pembrolizumab
The purpose of this study is to learn how to use blood tests to better predict how patients with non-small cell lung cancer, who are taking pembrolizumab for cancer treatment, will respond to treatment with pembrolizumab, and to…
- Trial name
- NCT04791215
- Testing
- Observational
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Columbia University
Sarcoma, Epithelioid Sarcoma
A Study of Talimogene Laherparepvec (T-VEC) in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma
The purpose of this study is to determine how well the combination of therapy of talimogene laherparepvec (T-VEC) and pembrolizumab works in the treatment of patients with sarcoma.
- Conditions
- Sarcoma, Epithelioid Sarcoma, Cutaneous Angiosarcoma
- Trial name
- NCT03069378
- Testing
- Talimogene Laherparepvec (T-VEC), Pembrolizumab
- Where
- 5 sites in United States
- Volunteers
- 41 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Metastatic Endometrial Cancer
Efficacy Assessment of Lenvatinib Associated with Pembrolizumab in Metastatic Endometrial Cancer: a French Multicentric Retrospective Early Access Program-based Study
LARENA is a multicentric retrospective study (secondary use of data) of consecutive patients prospectively registered in the lenvatinib plus pembrolizumab French early access program (Temporary Authorisation for Use).
- Trial name
- LARENA (NCT06599463)
- Where
- 24 sites in France
- Volunteers
- 351 people
- Sponsor
- ARCAGY/ GINECO GROUP